Aucuba Sciences

Pre-clinical

London, United KingdomFounded 2019aucubasciences.com

Aucuba Sciences is a private, preclinical-stage biotech focused on developing transformative therapies for neurodegenerative diseases by targeting the fundamental biology of aging. The company's core technology platform is built on research into cellular senescence and proteostasis, aiming to develop disease-modifying treatments rather than symptomatic relief. With a strong scientific foundation and experienced leadership team, Aucuba is working to advance its lead candidate toward clinical development while exploring broader applications of its aging-focused platform. The company represents a novel approach in the competitive neurodegeneration space, seeking to alter disease progression rather than merely manage symptoms.

Founded

2019

Employees

1-10

Focus

Ophthalmology

AI Company Overview

Technology Platform

Aging biology platform targeting cellular senescence, proteostasis, and mitochondrial function to develop disease-modifying therapies for neurodegenerative conditions.

Funding History

Total raised: $2.5M

Seed$2.5MUndisclosedMay 15, 2021

Opportunities

Aucuba has the opportunity to pioneer a new class of neurodegeneration therapies by targeting aging biology rather than specific pathological proteins.

Success could lead to expansion into other age-related neurological conditions and potentially broader aging-related indications.

The growing interest in geroscience from both investors and large pharma creates potential partnership and exit opportunities.

Risk Factors

The company faces high scientific risk as its novel approach to neurodegeneration remains unproven in humans.

As a preclinical, private company, it depends on continued funding through lengthy development phases.

It operates in a highly competitive space against well-resourced competitors with more advanced clinical programs.

Competitive Landscape

Aucuba competes against large pharma with amyloid-targeting antibodies (Biogen/Eisai, Eli Lilly) and biotech companies pursuing alternative mechanisms like neuroinflammation (Alector) or senescence (Unity). Its differentiation lies in its specific focus on CNS aging mechanisms, but it must demonstrate superior efficacy or safety to overcome entrenched competitors.